Safety Study of Pyridostigmine in Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Heart Failure
Interventions
DRUG

Pyridostigmine Bromide

15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue.

Trial Locations (1)

10016

New York University Langone Medical Center, New York

All Listed Sponsors
collaborator

Nathan Kline Institute for Psychiatric Research

OTHER

collaborator

Oklahoma State University

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

NYU Langone Health

OTHER

NCT01415921 - Safety Study of Pyridostigmine in Heart Failure | Biotech Hunter | Biotech Hunter